Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Non-Malignant Channel is supported with funding from Agios (Gold).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2022 | Updates from the HOPE-B trial: etranacogene dezaparvovec in adults with hemophilia B

In this video, Steven Pipe, MD, University of Michigan, Ann Arbor, MI, shares some updates from the Phase III HOPE-B trial, which is evaluating etranacogene dezaparvovec, an investigational gene therapy, in adult patients with severe or moderately severe hemophilia B (NCT03569891). In this study, patients with or without pre-existing AAV5 neutralizing antibodies received etranacogene dezaparvovec. Dr Pipe further discusses the results of this study, including factor IX activity, annualized bleed rate (ABR), and adverse events (AEs) observed. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Sanofi: Consultancy; Sangamo Therapeutics: Consultancy; Takeda: Consultancy; CSL Behring: Consultancy; UniQure: Consultancy; Freeline: Consultancy; Novo Nordisk: Consultancy; Regeneron/Intellia: Consultancy; Siemens: Research Funding; Spark Therapeutics: Consultancy; BioMarin Pharmaceutical Inc.: Consultancy; HEMA Biologics: Consultancy; Apcintex: Consultancy; Pfizer: Consultancy; ASC Therapeutics: Consultancy; Roche/Genentech: Consultancy; Bayer: Consultancy; Yewsavin: Research Funding.

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.